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In 1989 approximately wI,OfYl persons in the United States 
underwent coronary revascularization with almost equal 
numbers of patients treated with percutaneous transluminal 
coronary angioplasty (FTCA) and coronary anery bypass 
surgery. The role of surgery in comparison with an initial 
strategy of medical therapy (uas the focus of several large 
randomized trials and multiple registry and data bank studies 
in the 1970s and 1980s. As a result. the impact of coronary 
bvoass surgery in com!xrison with medical therapy on 
s&ival and symptom rciief in ditTerent patient subseis has, 
bv and laree. beer clarified (I). The emphasis in the 1990s 
his chiftedtoward identifying the p&red method of W- 
vascolarizatioo-whether this be coronary angioplasty or 
bypass surgery (2-4). The controversy is particularly rele- 
vant in patients with multivessel disease, who now represent 
a large segment of the group undergoing ballooa angiiplasty 
(3-14). 
The present study. The rcpxt by O’Keefc et al. (15) in 
this issue of the Journal is timely and important but also 
highlights the relative paucity of published dats on which the 
decision to perform surgery or angioplasty must be based. 
Regrettably. approximately 1 I years after the initial use of 
coronary angioplasty, we do not yet have resulls from 
randomized trials and, in the absence of such data, have to 
rely on the reported results of clinical experience. In this 
regwd the series by O’Keeie et al. (15) can serve as a 
benchmlrk for comparison with other published data. It 
should be kept in mind, however, that individual scrtea tiw 
are characterized by expertise and excellence also remind us 
of the importance of comparative studies and randomized 
trials that take into account the vagaries and biases involved 
in the selection of padems for a particular procedure. 
Double versw trtple v-t dtseme. Multivessel disease 
should not be viewed as a homogeneous clinical eolity. The 
natural history of patients with double or triple vessel 
disease can vary and there are major differences in the 
distribution of double or triple vessel disease in patients who 
undergo aagioplasty in comparison with those who have 
coronary artw bypass surgery. For example, among angio- 
pkwy p&ientswi& multivessel disease, t&le kennel disease 
was present in 41% of patients in the recent cohort of the 
National Heart, Lung, and Blaod Institute’s (NHLBI) FTCA 
registry (5): 26% in the series of Deligooul et al. (6); 21% in 
the Emory University Hospital experience from 1985 to 1988 
(4): and in 38% of 867 patients at ourown institution (Bell M, 
personal communica~on. June 1990). In contrasI, in large 
series of patients undergoing coronary bypass surgery. triple 
vessel disease was present in 62% of patients in the Core- 
nary Artery Surgery Study (CA53 registry (16); 62% (en- 
eluding patients with left main coronary disease) in the 
Emory University Hospital series (4): 7% in the Cleveland 
Clinic exaerience of the first l.ooO patients who had bypass 
surgery ia 1990 (Loop FD. personal communication, June 
1990): and in 78% ol oatients in a sin& surt~on’s series at 
the Mayo Clinic (Sch&THV, personaicomm&ation, June 
1990). It appears, therefore, that in reported surgical series 
approximately two thirds of patients with multivessel dis- 
ease have triple vessel disease: the reverse is evident in the 
coronary angioplasty experience. In the study of O’Keefe et 
al. (15)there isapredominance oftriple vessel disease (54%) 
but this is probably a partial consequence of their inclusion 
criteria be&e p&e& with two vessel disease who under- 
went dilation of only one vessel were specifically excluded 
and categorized as having had single vessel angioplasty (5). 
Role of kfl ventricular dysfunclion. In many comparative 
studies of bypass surgery kd medical therapy. left ventric- 
ular dysfunction has emerged asB powerful determinant of 
late prognosis (I). Moreover, in patients with left ventricular 
dysfunction and multivessel disease surgery has been found 
to be associated with improved morbidity and mortality in 
comparison with medical therapy (I ). The role of angioplasty 
in similar patients with multivessel disease and left ventric- 
ular dysfunction has not been adequately addressed in many 
large reported angioplasty series, For example, only 19% of 
patients in the recent cohort in the NHLBJ FTCA registry (5) 
had an ejection fraction ~0.50. a percentage similar to the 
23% in the Mayo Clinic experience, and only 12% of patients 
in Ihe series of O’Keefe et al. (15) had an ejection fraction 
cO.40. In the 1988 experience at Emory Umverwy 141. ,m 
cicction fraction 10.50 was ore\ent in onlv IV of oauent> 
tlndergoing angioplasty in cdntrast with a~proxm&ly 3OV 
in surgically treated patients. However. thi, preddcction to 
perform angioplasty in patients uith relarivcly well prc- 
served left ventricular functmn IF appropnatc hecawe ,he 
acute consequences of anpioplasty Mure. namely. emw 
gency coronary bypass surgery or acute myocardlal ~nfxc- 
tion, although somewhat mfrequent. become fx more wri. 
ous in patients with preexisting left ventrular dy\functlon 
(17). Although the current tendency to perform angmplilrty 
primarily in patients with double vessel diwxo .md in ihox 
with good left ventricular function may well he prudcnr. thn 
does highlight the potential for error in using the publi\hcd 
literature to draw comparisons between the rewIt\ of the 
two pmcedures in multivessol disease. To their credit. 
O’Keefe et al. (15) do not make any direct compen\on~ and 
correctly emphasize the importance of randomued trial\ of 
coronary angioplasty and bypass surgery that are under way. 
Results of Angiophty 
Early results. The low mortality and short-term comply- 
cation rate in the series of O’Keefe et al. (ISI attea to the 
expertise and experience of the investigators and was simdar 
to that achieved in patients with smgle ve~el disease except 
for the surprisingly low incidence of necessity for bypass 
surgery in patients with multivessel diseze. Their compli- 
cation rate is lower :han that reported in other series of 
patients with multivessel disease and contrasts with the 
experience in the NHLBI PICA registry (II). in which 
morbidity and mortality were higher with an increasing 
number of diseased vessels. The latter finding is not wrpris- 
ing because many complicadons arc lesion related and not 
entirely patient specific: the apparent discrepancy between 
the two series probably relates to differences among the 
palienl groups. As stated by the authon ll51. patients with 
multivessel disease in whom the procedure ws aborted after 
a complication during angioplasty of the initially dilated 
vessel were not included in this report but calcgorizcd under 
“single vessel angioplasty.” This definition led to improved 
results in patients with multivessel dlseaz and could itic- 
count for soroe of the differences between the recolt~ m thi, 
series and those of other published studies. It would be 
interesting to know how many patients with multivewl 
disease aclually were in the group in which the procedure 
was aborted after failed angioplasty of the initially dilated 
vessel; the morbidity and mortality in this subset are also 
inc!dencc of complete rewwlawalion m comprriion 191th 
pawni~ am the NHLBI PICA rcgi\try (5). Nonethelex 
pcrh.p\ Ihc mu\, cncnurag,n$ a\pecr of there data IF Iha, 
only IV; of p&~ents underwent comnury iartery bypi,\\ 
>urgc~y ‘1, 5 year\ and the majority uf re~tcno~c\ appwently 
wpondsd 10 repeat dilation with good law fuunetionai out- 
come. Owrall. event-free wviwl. d&e,1 as freedom from 
death. myocdrdral inhrction or need for surgery. WE also 
cncoor,~gm:ly low. ;\lthough the dcfinltion of tnfarction was 
lhmltcd IO Q ~+avc infwction. In any analysis of the immedi- 
iw rcwI~\ of the procedure II II reasonahlc to exclude iloo-Q 
wake mf.trcuon. beeawe it is difficult to identify thia during 
the perioperative period of eoronxy bypass surgery. Haw- 
ever. in regard to late outcome. any horpllal admiirion 
prccipitarcd by prolonged che<t pain in association with a 
nw m cardiac enzymes conwcnt wth int’xction rhould be 
categonxd as mfxction whether or not Q waves develop. 
Conclusions. Coronary sngioplarry is wfe end effective 
and wdl wntmue to he urcd in selected patients with 
muIwes%I disease. Emerging :echnalogy and. particularly. 
any reduction in the incidence of re~teno\is will expand to 
utiliti If other <todies can document that for mOSi oatients 
who undergo sngioplasty coronary bypass sorgery’can be 
postponed for several years v’ithout compromise to quality 
of life. then the value of angtoplauy in mullivessel dIreace 
WI undeniabl) bc enhanced. 
Nonelhele\\. it should be emphastred that the specific 
indicimon\ fir coronary angioplarty in the wide ,pcctrum of 
pntient\ with multivessel disease remain undefined. Rigor- 
oux woto~y of randomized tnals. including analyses of 
nonrandomzed patients entered into a registry. may not 
provide all the answers hut will probably clarify the iwes 
further 10 \pecdic subsets of patient-. Until the results of 
thw sIudie* are available. the data from large series such a? 
that from O‘Kccfc et al. 1 IS) .?re helpful and needed. 

